Lonza Group AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other
pharmaceutical manufacturers in Europe:
H. Lundbeck A/S
sales of 15.63 billion Danish Kroner [US$2.26 billion]
of which 19%
was Other Pharmaceuticals),
(4.18 billion Euro [US$4.49 billion]
of which 100%
was Biopharmacy), and
based in France
(1.67 billion Euro [US$1.79 billion]
During the year ended December of 2016, sales at
Lonza Group AG were 4.13 billion Swiss Francs (US$4.14 billion).
increase of 8.7%
versus 2015, when the company's sales were 3.80 billion Swiss Francs.
This was the third consecutive year of growth at Lonza Group AG.